Bevacizumab - Biologic Drug Details
✉ Email this page to a colleague
Summary for bevacizumab
Tradenames: | 1 |
High Confidence Patents: | 24 |
Applicants: | 6 |
BLAs: | 6 |
Suppliers: see list | 5 |
Recent Clinical Trials: | See clinical trials for bevacizumab |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for bevacizumab |
Recent Clinical Trials for bevacizumab
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 1/Phase 2 |
Nykode Therapeutics ASA | Phase 2 |
University of Nebraska | Phase 1 |
Recent Litigation for bevacizumab
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC. | 2023-11-17 |
Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd. | 2023-10-20 |
Genentech, Inc. v. Biogen MA Inc. | 2023-07-13 |
See all bevacizumab litigation
PTAB Litigation
Petitioner | Date |
---|---|
Illumina, Inc. et al. | 2021-07-20 |
Laboratory Corporation of America Holdings et al. | 2021-05-28 |
Quest Diagnostics Incorporated | 2021-04-15 |
Pharmacology for bevacizumab
Mechanism of Action | Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions |
Established Pharmacologic Class | Vascular Endothelial Growth Factor Inhibitor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for bevacizumab Derived from Brand-Side Litigation
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2035-07-31 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2028-07-08 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2028-07-08 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2032-09-17 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2034-04-23 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2030-08-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
2) High Certainty: US Patents for bevacizumab Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2014-01-25 | Company disclosures |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2020-08-05 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for bevacizumab Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2035-03-27 | Patent claims search |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2032-09-12 | Patent claims search |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2035-12-11 | Patent claims search |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2034-02-06 | Patent claims search |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2035-03-30 | Patent claims search |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2033-03-13 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for bevacizumab
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | H08507680 | ⤷ Sign Up |
Japan | 2005000165 | ⤷ Sign Up |
Finland | 117509 | ⤷ Sign Up |
Australia | 1273697 | ⤷ Sign Up |
Austria | E182625 | ⤷ Sign Up |
Australia | 1696095 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for bevacizumab
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
CA 2006 00025 | Denmark | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB |
300238 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060630 |
2006C/035 | Belgium | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/06/346/001 20060628 |
06C0024 | France | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627 |
SPC 025/2006 | Ireland | ⤷ Sign Up | SPC 025/2006: 20070523, EXPIRES: 20200124 |
23/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.